Last reviewed · How we verify
amodiaquine-artesunate versus amodiaquine
Amodiaquine-artesunate is a fixed-dose combination antimalarial that combines a quinoline derivative with a fast-acting artemisinin to kill malaria parasites through multiple mechanisms.
Amodiaquine-artesunate is a fixed-dose combination antimalarial that combines a quinoline derivative with a fast-acting artemisinin to kill malaria parasites through multiple mechanisms. Used for Uncomplicated malaria (Plasmodium falciparum and other species), Malaria treatment in endemic regions.
At a glance
| Generic name | amodiaquine-artesunate versus amodiaquine |
|---|---|
| Sponsor | Charite University, Berlin, Germany |
| Drug class | Antimalarial combination |
| Target | Malaria parasite heme detoxification pathway; artemisinin-derived endoperoxide bridge |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amodiaquine is a 4-aminoquinoline that inhibits heme polymerization in malaria parasites, while artesunate is a semi-synthetic artemisinin derivative that generates reactive oxygen species and damages parasite proteins. The combination provides rapid parasite clearance (artesunate) with sustained suppression (amodiaquine), reducing treatment duration and improving efficacy against drug-resistant strains.
Approved indications
- Uncomplicated malaria (Plasmodium falciparum and other species)
- Malaria treatment in endemic regions
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Diarrhea
Key clinical trials
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (PHASE3)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (PHASE3)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia) (PHASE3)
- Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005 (PHASE4)
- Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar (PHASE4)
- Effectiveness of Intermittent Preventive Treatment for Malaria in Children (PHASE2, PHASE3)
- Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy (PHASE3)
- Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: